drugset / Trial / NCT06624072

A Study in Healthy People to Compare 2 Different Formulations of Nerandomilast Tablets When Taken With or Without Food

NCT06624072

Phase 1 Completed 15 enrolled Boehringer Ingelheim
RandomizedCrossoverOpen-labelTreatment

Summary

The main objective of this trial is to investigate two different formulations of nerandomilast and the effect of food on the pharmacokinetics of the new formulation following oral administration.

Timeline

Start
2024-10-15
Primary completion
2024-11-22
Completion
2024-11-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Nerandomilast Small molecule 1 mg Oral
Subject Nerandomilast Small molecule 18 mg Oral

Indications

No indication recorded.